Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 1:00 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 745–768 of 12,520 matching trials from the live ClinicalTrials.gov search.

Filters: Miami, Florida Clear all

Conditions: Ulcerative Colitis (UC)
Interventions: Upadacitinib (ABT-494), Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 16 Years to 75 Years
Enrollment: 950 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 147
States / cities: Mobile, Alabama • Chandler, Arizona • Mesa, Arizona + 111 more

Conditions: Moderate Liver Impairment, Severe Liver Impairment
Interventions: BMS-986036; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 21 Years to 75 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 3
States / cities: Miami, Florida • Orlando, Florida • San Antonio, Texas

Conditions: HER2-positive Breast Cancer
Interventions: tucatinib, placebo, T-DM1; Drug
Lead sponsor: Seagen, a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 466 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2029
U.S. locations: 321
States / cities: Mobile, Alabama • Gilbert, Arizona • Goodyear, Arizona + 180 more

Conditions: Parkinson's Disease
Interventions: Standard of Care; Other
Lead sponsor: Bayer; Industry
Eligibility: 45 Years to 75 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 27
States / cities: Phoenix, Arizona • Tucson, Arizona • Fountain Valley, California + 23 more

Conditions: Diarrhea-predominant Irritable Bowel Syndrome
Interventions: BOS-589, Placebo; Drug
Lead sponsor: Boston Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 133 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 58
States / cities: Anniston, Alabama • Huntsville, Alabama • Chandler, Arizona + 48 more

Conditions: Lung Cancer
Interventions: bevacizumab, pemetrexed disodium; Biological · Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 248
States / cities: Anchorage, Alaska • Scottsdale, Arizona • Little Rock, Arkansas + 161 more

Conditions: Renal Impairments
Interventions: EDG-7500; Drug
Lead sponsor: Edgewise Therapeutics, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 2
States / cities: Miami, Florida • Orlando, Florida

Conditions: Autism Spectrum Disorder, Social Communication Delay
Interventions: Online Parent Training in Early Behavioral Intervention (OPT-In-Early); Behavioral
Lead sponsor: Florida International University; Other
Eligibility: 14 Months and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Colorectal Cancer
Interventions: Irinotecan, capecitabine [Xeloda]; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2005
U.S. locations: 10
States / cities: Hoover, Alabama • La Jolla, California • Miami, Florida + 7 more

Conditions: Advanced Solid Tumor, Metastatic Cancer, Cutaneous Melanoma, Non-Small Cell Lung Cancer
Interventions: AU-007, Aldesleukin, Avelumab, Nivolumab; Drug
Lead sponsor: Aulos Bioscience, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 159 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 10
States / cities: Miami, Florida • Grand Rapids, Michigan • Minneapolis, Minnesota + 7 more

Conditions: Exocrine Pancreatic Insufficiency (EPI), Cystic Fibrosis (CF)
Interventions: MS1819, Porcine PERT; Drug
Lead sponsor: Entero Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 10
States / cities: Long Beach, California • Altamonte Springs, Florida • Miami, Florida + 7 more

Conditions: Diabetes Mellitus
Interventions: Albiglutide 30 mg, Albiglutide 50 mg, Albiglutide matching placebo; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 9,463 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 146
States / cities: Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 125 more

Conditions: Asthma
Interventions: Generic Budesonide/Formoterol Fumarate Dihydrate, Symbicort® (Budesonide/Formoterol Fumarate Dihydrate), Placebo; Drug
Lead sponsor: Actavis Inc.; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 1,714 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 17
States / cities: Surprise, Arizona • Huntington Beach, California • San Jose, California + 12 more

Conditions: Peripheral Nerve Injury(Ies)
Interventions: Not listed
Lead sponsor: Major Extremity Trauma Research Consortium; Other
Eligibility: 18 Years to 65 Years
Enrollment: 242 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 17
States / cities: Denver, Colorado • Miami, Florida • Bloomington, Indiana + 13 more

Conditions: Triple Negative Breast Cancer
Interventions: adagloxad simolenin combined with OBI-821, Globo H IHC Assay, Standard of care treatment; Biological · Device · Other
Lead sponsor: OBI Pharma, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 575 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 12
States / cities: La Jolla, California • San Diego, California • San Francisco, California + 9 more

Conditions: Parkinson Disease
Interventions: Omnidirectional stimulation, Directional stimulation; Device
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: Not listed
Enrollment: 234 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 21
States / cities: Sacramento, California • Aurora, Colorado • Gainesville, Florida + 16 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: tetomilast, placebo; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 40 Years to 75 Years
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 15
States / cities: Birmingham, Alabama • Torrance, California • Kissimmee, Florida + 12 more

Conditions: Severe Aortic Stenosis
Interventions: Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI), Surgical Aortic Valve Replacement (SAVR), Medtronic CoreValve® Evolut R System Transcatheter Aortic Valve Implantation (TAVI); Device · Procedure
Lead sponsor: Medtronic Cardiovascular; Industry
Eligibility: Not listed
Enrollment: 1,746 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2026
U.S. locations: 65
States / cities: Phoenix, Arizona • Hollywood, California • La Jolla, California + 55 more

Conditions: Healthy
Interventions: I-PAS; Device
Lead sponsor: Neurolign; Industry
Eligibility: 6 Years to 18 Years
Enrollment: 600 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 2
States / cities: Miami, Florida • Pittsburgh, Pennsylvania

Conditions: Meningioma
Interventions: Cabozantinib; Drug
Lead sponsor: Baptist Health South Florida; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 3
States / cities: Miami, Florida • New York, New York • Nashville, Tennessee

Conditions: Male Infertility
Interventions: Diagnostic; Diagnostic Test
Lead sponsor: Aytu BioPharma, Inc.; Industry
Eligibility: 21 Years to 45 Years · Male only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 6
States / cities: Miami, Florida • New Orleans, Louisiana • Rochester, Minnesota + 3 more

Conditions: Hematological Malignancy
Interventions: DxFLEX 10C; Device
Lead sponsor: Beckman Coulter, Inc.; Industry
Eligibility: Not listed
Enrollment: 527 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 4
States / cities: Aliso Viejo, California • Miami, Florida • Lewisville, Texas + 1 more

Conditions: Diabetes Mellitus, Type 1
Interventions: Insulin Lispro, regular human insulin, recombinant human hyaluronidase PH20, Insulin glargine; Drug
Lead sponsor: Halozyme Therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 8
States / cities: Aurora, Colorado • Miami, Florida • Detroit, Michigan + 5 more

Conditions: Psoriasis
Interventions: BMS-986165, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 1,466 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 101
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 77 more

Search by objective public record fields.

A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC)

A Study to Evaluate the Drug Levels, Safety, and Tolerability of BMS-986036 in Participants With Normal Liver Function and Participants With Moderate and Severe Liver Impairment

A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer

A US Study That Observes How Parkinson's Disease Changes Over Time in Patients Who Still Have Movement Symptoms Despite Taking Parkinson's Medications

Study to Evaluate the Efficacy, Safety, and Tolerability of BOS-589 in the Treatment of Patients With Diarrhea-predominant Irritable Bowel Syndrome (IBS-D)

Pemetrexed Disodium and Bevacizumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

A Study to Evaluate EDG-7500 in People With Renal Impairment

A Digital Health Parent-Training Intervention for Children With Social Communication Delays

A Study of Xeloda (Capecitabine) in Patients With Advanced and/or Metastatic Colorectal Cancer

Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

OPTION 2: A Trial to Assess the Safety and Efficacy of MS1819 in Enteric Capsules in Patients With Cystic Fibrosis

Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus

Randomized, Placebo-Controlled, Multidose, Study Comparing Generic Budesonide/Formoterol Fumarate Dihydrate to Symbicort® in Asthmatic Participants

Study of Nerve Repair and Reconstruction Associated With Major Extremity Trauma

Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC

Clinical Evaluation of the Infinity Deep Brain Stimulation System

Pilot Study of Tetomilast in Chronic Obstructive Pulmonary Disease (COPD) Associated With Emphysema

Safety and Efficacy Study of the Medtronic CoreValve® System in the Treatment of Severe, Symptomatic Aortic Stenosis in Intermediate Risk Subjects Who Need Aortic Valve Replacement (SURTAVI).

Normative Oculomotor and Vestibular Data in Pediatric Population

Cabozantinib for Patients With Recurrent or Progressive Meningioma

A Clinical Evaluation of Semen Quality Using the MiOXSYS™ System 2.0

DxFLEX 10C Clinical Study

Safety Study of Subcutaneously-Injected Prandial INSULIN-PH20 NP Compared to Insulin Lispro Injection in Participants With Type 1 Diabetes Mellitus

Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis